Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching From Tirzepatide to Zenagamtide in Overweight or Obesity
NCT07868354Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Oct 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of amycretin in Overweight, obesity and type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events. Started Oct 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
Overweightobesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07868354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07868354.